Merit Medical Systems Inc (NASDAQ:MMSI) delivered a mixed financial performance for the fourth quarter of its 2025 fiscal year, with revenue surpassing expectations but earnings per share falling slightly short. The medical device manufacturer's results, released on February 24, 2026, have elicited a muted but positive initial reaction from investors in after-hours trading.
Quarterly Earnings Versus Estimates
The company’s top-line strength was the standout feature of the quarter. Merit Medical reported Q4 revenue of $393.9 million, which represents a solid 10.9% increase compared to the same period last year. This figure notably exceeded the analyst consensus estimate of approximately $397.7 million. On the bottom line, the company posted non-GAAP earnings per share (EPS) of $1.04. While this is a healthy profit, it came in just below the analyst estimate of $0.97 per share.
- Reported Q4 Revenue: $393.9 million
- Analyst Estimate for Q4 Revenue: ~$397.7 million
- Reported Q4 Non-GAAP EPS: $1.04
- Analyst Estimate for Q4 Non-GAAP EPS: $0.97
Market Reaction and Recent Performance
Following the earnings announcement, Merit Medical's stock saw an after-market increase of approximately 3.6%. This upward move suggests investors are focusing on the revenue beat and the company's forward guidance rather than the slight EPS miss. The stock's performance over recent weeks has been relatively stable, with modest gains over the past one and two-week periods and a nearly flat performance over the last month, indicating a lack of major pre-earnings speculation.
Fiscal Year 2026 Guidance and Analyst Expectations
A key component of the earnings release was the company's initial guidance for the full 2026 fiscal year. Merit Medical provided a revenue outlook with a midpoint of $1.62 billion. This projection sits slightly above (by 0.9%) the current analyst consensus estimate of $1.637 billion for the year, indicating management confidence in continued growth. The company did not provide specific EPS guidance in the press release highlights.
- Company's FY2026 Revenue Guidance (Midpoint): $1.62 billion
- Analyst Consensus Estimate for FY2026 Revenue: $1.637 billion
Press Release Highlights
Beyond the core financial metrics, the company's press release emphasized strong organic growth, with constant currency revenue up 10% and organic constant currency revenue up 7% for the quarter. The full-year results for fiscal 2025 were also summarized, showcasing the company's overall annual performance leading into the new guidance. The report underscores Merit Medical's ongoing momentum across its cardiovascular and endoscopy product portfolios.
Looking Ahead
The focus now shifts to the first quarter of fiscal 2026. Analysts are currently modeling Q1 revenue of approximately $386.7 million and earnings per share around $0.91. Merit Medical's ability to meet or exceed these early-quarter estimates will be critical in determining whether the positive sentiment from the Q4 revenue beat and guidance can be sustained.
For a detailed breakdown of historical earnings, future estimates, and analyst ratings, readers can review the data available on the Merit Medical Systems earnings estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.